AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31595259 — intervention group
Group type: COMPARATOR
Intervention: Standard care provided by health professionals.
Number of subjects: 410
Study 31595353 — intervention group
Group type: EXPERIMENTAL
Intervention: POCUS (Point-of-care ultrasound)
Number of subjects: 80
Study 31595377 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversation more than 20 minutes
Number of subjects: 386
Study 31595377 — intervention group
Group type: EXPERIMENTAL
Intervention: Covering many topics
Number of subjects: 386
Study 31595377 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a significant other
Number of subjects: 386
Study 31595377 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision making
Number of subjects: 386
Study 31595377 — intervention group
Group type: COMPARATOR
Intervention: Not receiving a specific diagnosis
Number of subjects: 386
Study 31595482 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated quadrivalent influenza vaccine (IIV4)
Number of subjects: 1060
Study 31595670 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis treatment in hemophilia
Number of subjects: 0
Study 31595670 — intervention group
Group type: COMPARATOR
Intervention: Hemophilia
Number of subjects: 0
Study 31595793 — intervention group
Group type: EXPERIMENTAL
Intervention: Dosage-controlled cannabis capsules; specific dosage and duration not available
Number of subjects: 0
Study 31595982 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcimimetic treatment (30-60 mg daily for 4 weeks)
Number of subjects: 110
Study 31596034 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab induction
Number of subjects: 40
Study 31597157 — intervention group
Group type: EXPERIMENTAL
Intervention: Less intensive chemotherapy with autotransplant
Number of subjects: 125
Study 31597157 — intervention group
Group type: EXPERIMENTAL
Intervention: Autotransplant
Number of subjects: 125
Study 31597157 — intervention group
Group type: EXPERIMENTAL
Intervention: White blood cells ≥100 × 10^9/L at study entry
Number of subjects: 125
Study 31597157 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving an autotransplant
Number of subjects: 125
Study 31598047 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 6 mg sublingually as premedication
Number of subjects: 120
Study 31598047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 31598139 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg orally once daily
Number of subjects: 3480
Study 31598346 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rehabilitation protocol with a short-term immobilization period of 2 weeks.
Number of subjects: 115
Study 31598346 — intervention group
Group type: COMPARATOR
Intervention: Conventional protocol with immobilization of the shoulder for over 4 weeks.
Number of subjects: 115
Study 31598646 — intervention group
Group type: EXPERIMENTAL
Intervention: Flublok (recombinant protein-based)
Number of subjects: 85
Study 31598646 — intervention group
Group type: COMPARATOR
Intervention: Flucelvax (cell-based)
Number of subjects: 85
Study 31598646 — intervention group
Group type: COMPARATOR
Intervention: Fluzone (egg-based)
Number of subjects: 85
Study 31598646 — intervention group
Group type: COMPARATOR
Intervention: Fluzone High-Dose (egg-based)
Number of subjects: 85
Study 31599001 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg b.d.
Number of subjects: 1157
Study 31599001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1157
Study 31599480 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-intensity conditioning regimen (RIC) containing alemtuzumab, fludarabine, melphalan, and thiotepa
Number of subjects: 4
Study 31599736 — intervention group
Group type: EXPERIMENTAL
Intervention: Human-centered design (HCD) methods applied to evidence-based psychosocial interventions (EBPIs)
Number of subjects: 0
Study 31599736 — intervention group
Group type: EXPERIMENTAL
Intervention: Iteratively designed solutions to usability challenges
Number of subjects: 0
Study 31599736 — intervention group
Group type: EXPERIMENTAL
Intervention: Stakeholder involvement in design of EBPI modifications
Number of subjects: 0
Study 31599736 — intervention group
Group type: EXPERIMENTAL
Intervention: HCD-informed modifications and solutions
Number of subjects: 0
Study 31599928 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitrate (1 g/L in drinking water for 7 days)
Number of subjects: 2
Study 31599928 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitrite (10 μmol/min infusion for 30 minutes)
Number of subjects: 2
Study 31599928 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (0.9% saline)
Number of subjects: 2
Study 31599951 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam
Number of subjects: 48
Study 31600167 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose capecitabine (150 mg bid)
Number of subjects: 11
Study 31600167 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose capecitabine (300 mg bid)
Number of subjects: 11
Study 31600167 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose capecitabine (450 mg bid)
Number of subjects: 11
Study 31601186 — intervention group
Group type: EXPERIMENTAL
Intervention: Cynomolgus macaques
Number of subjects: 12
Study 31601186 — intervention group
Group type: COMPARATOR
Intervention: Healthy humans
Number of subjects: 12
Study 31601199 — intervention group
Group type: EXPERIMENTAL
Intervention: EQUIP organizational intervention to promote equity in health care
Number of subjects: 0
Study 31601588 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal night-eating pattern (consumption of meal and snack during 1900-0659 hours)
Number of subjects: 200
Study 31601588 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring at 18-24 weeks' gestation
Number of subjects: 200
Study 31601588 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test and insulin test at 24-28 weeks' gestation
Number of subjects: 200
Study 31601596 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glyburide administered within 8 hours of injury
Number of subjects: 10
Study 31601596 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glyburide
Number of subjects: 10
Study 31601602 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated early warning system (EWS) - Rothman Index by PeraHealth
Number of subjects: 1874
Study 31601602 — intervention group
Group type: COMPARATOR
Intervention: Physician judgement
Number of subjects: 1874
Study 31601602 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model of physician and EWS predictions
Number of subjects: 1874
Study 31601604 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthened growth monitoring and promotion (GMP) activities in community clinics (CCs)
Number of subjects: 30
Study 31601604 — intervention group
Group type: COMPARATOR
Intervention: No intervention to strengthen GMP implementation in community clinics (CCs)
Number of subjects: 30
Study 31601646 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node detection with indocyanine green
Number of subjects: 176
Study 31601692 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment according to AIEOP-BFM protocols
Number of subjects: 0
Study 31601728 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI ≥30 kg/m
Number of subjects: 10003
Study 31602237 — intervention group
Group type: COMPARATOR
Intervention: Sphingolipid metabolites measurement (So1P, GluCer, SM, Sa, So)
Number of subjects: 245
Study 31602237 — intervention group
Group type: EXPERIMENTAL
Intervention: So1P and Sa
Number of subjects: 245
Study 31602237 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curve analysis
Number of subjects: 245
Study 31602320 — intervention group
Group type: EXPERIMENTAL
Intervention: FoundationACT™ ctDNA assay (Foundation Medicine, Cambridge, MA, USA)
Number of subjects: 96
Study 31602320 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive genomic profiling (CGP) of tumor tissue sample
Number of subjects: 96
Study 31602518 — intervention group
Group type: EXPERIMENTAL
Intervention: Open abdomen treatment in obese patients
Number of subjects: 591
Study 31602644 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Atkins diet
Number of subjects: 63
Study 31603393 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial barriers (no insurance and underinsurance)
Number of subjects: 797
Study 31603393 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral Artery Questionnaire (PAQ)
Number of subjects: 797
Study 31603393 — intervention group
Group type: EXPERIMENTAL
Intervention: EuroQol 5 (EQ5D) dimensions
Number of subjects: 797
Study 31603563 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory cleft (OC) opacification in CRS patients (average 63.7%)
Number of subjects: 148
Study 31603563 — intervention group
Group type: COMPARATOR
Intervention: Olfactory cleft (OC) opacification in control subjects (average 47.1%)
Number of subjects: 148
Study 31603563 — intervention group
Group type: EXPERIMENTAL
Intervention: CRSwNP patients
Number of subjects: 148
Study 31603563 — intervention group
Group type: EXPERIMENTAL
Intervention: CRSsNP patients
Number of subjects: 148
Study 31603563 — intervention group
Group type: EXPERIMENTAL
Intervention: Lund-Mackay score in CRSsNP patients
Number of subjects: 148
Study 31603563 — intervention group
Group type: EXPERIMENTAL
Intervention: Lund-Mackay score in CRSwNP patients
Number of subjects: 148
Study 31604171 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-assessed VAT volume
Number of subjects: 44
Study 31604171 — intervention group
Group type: EXPERIMENTAL
Intervention: SAT volume
Number of subjects: 44
Study 31604419 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol induction dose based on total body weight (TBW) scaled by phase angle value
Number of subjects: 40
Study 31604419 — intervention group
Group type: EXPERIMENTAL
Intervention: Guiding propofol induction dose according to baseline frailty score
Number of subjects: 40
Study 31604419 — intervention group
Group type: EXPERIMENTAL
Intervention: Determination of phase angle value
Number of subjects: 40
Study 31604778 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterozygous variants in DNA damage repair genes
Number of subjects: 0
Study 31604781 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle factors assessment including dietary pattern, physical activity, cardiovascular fitness, and sleep.
Number of subjects: 840
Study 31604781 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical history, socioeconomic status, alcohol and tobacco consumption, cognition, stress, anxiety, and early life experiences documentation.
Number of subjects: 840
Study 31604781 — intervention group
Group type: EXPERIMENTAL
Intervention: Body composition and bone density measurement by dual energy X-ray absorptiometry.
Number of subjects: 840
Study 31604781 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure, pulse wave velocity, and augmentation index measurement on two consecutive days.
Number of subjects: 840
Study 31604781 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic disease risk biomarkers measured in blood and urine samples.
Number of subjects: 840
Study 31604781 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA extraction for genetic analysis.
Number of subjects: 840
Study 31604781 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal sample collection for microbiome analysis.
Number of subjects: 840
Study 31604785 — intervention group
Group type: EXPERIMENTAL
Intervention: Transhepatic flow changes following major liver resection
Number of subjects: 50
Study 31604788 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 1 (22% refusal rate)
Number of subjects: 642
Study 31604788 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 2 (38% refusal rate)
Number of subjects: 642
Study 31604788 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 3 (62% refusal rate)
Number of subjects: 642
Study 31605106 — intervention group
Group type: EXPERIMENTAL
Intervention: larotrectinib 100 mg twice daily
Number of subjects: 1
Study 31605106 — intervention group
Group type: EXPERIMENTAL
Intervention: selitrectinib 100 mg twice daily
Number of subjects: 1
Study 31605106 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine, nab-paclitaxel and ADI-PEG 20
Number of subjects: 1
Study 31605106 — intervention group
Group type: COMPARATOR
Intervention: modified regimen of folinic acid, fluorouracil, irinotecan and oxaliplatin
Number of subjects: 1
Study 31605106 — intervention group
Group type: EXPERIMENTAL
Intervention: dabrafenib-trametinib combination therapy
Number of subjects: 1
Study 31605278 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard split dose of 4 l polyethylene glycol for bowel preparation
Number of subjects: 199
Study 31605278 — intervention group
Group type: EXPERIMENTAL
Intervention: Bristol stool form scale (BSFS) 1
Number of subjects: 199
Study 31605278 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal pain score during defecation < 2
Number of subjects: 199
Study 31605278 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting-to-defecation interval ≥ 4 h
Number of subjects: 199
Study 31605278 — intervention group
Group type: COMPARATOR
Intervention: No risk factors
Number of subjects: 199
Study 31605278 — intervention group
Group type: COMPARATOR
Intervention: 1 risk factor
Number of subjects: 199
Study 31605278 — intervention group
Group type: COMPARATOR
Intervention: 2 risk factors
Number of subjects: 199
Study 31605278 — intervention group
Group type: COMPARATOR
Intervention: 3 risk factors
Number of subjects: 199
Study 31605514 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week physical activity intervention
Number of subjects: 87
Study 31605514 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 87
Study 31605516 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated mental health resources via smartphone technology (Pocket Helper 2.0 app)
Number of subjects: 100
Study 31605516 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily tips and daily surveys from the Pocket Helper 2.0 app
Number of subjects: 100
Study 31605516 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated self-help system and app providing up-to-date resources
Number of subjects: 100
Study 31605516 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive features (telephone hotline and crowd-based emotional support tool)
Number of subjects: 100
Study 31605516 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant retention
Number of subjects: 100
Study 31605516 — intervention group
Group type: EXPERIMENTAL
Intervention: Problems with phones (theft, loss, technological issues)
Number of subjects: 100
Study 31605903 — intervention group
Group type: EXPERIMENTAL
Intervention: AHI > 15
Number of subjects: 302
Study 31605903 — intervention group
Group type: COMPARATOR
Intervention: AHI < 15
Number of subjects: 302
Study 31605903 — intervention group
Group type: EXPERIMENTAL
Intervention: AHI
Number of subjects: 302
Study 31605903 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal hypoxemia (T90%)
Number of subjects: 302
Study 31605903 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% oxygen desaturation index (ODI3)
Number of subjects: 302
Study 31606044 — intervention group
Group type: EXPERIMENTAL
Intervention: S5 methylation classifier
Number of subjects: 316
Study 31606044 — intervention group
Group type: COMPARATOR
Intervention: HPV16/18 detection
Number of subjects: 316
Study 31606044 — intervention group
Group type: COMPARATOR
Intervention: Cytology
Number of subjects: 316
Study 31606309 — intervention group
Group type: EXPERIMENTAL
Intervention: MELD-XI score > 12
Number of subjects: 11091
Study 31606309 — intervention group
Group type: EXPERIMENTAL
Intervention: MELD-XI score
Number of subjects: 11091
Study 31606419 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel infusion
Number of subjects: 75
Study 31606880 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin 50 mg
Number of subjects: 2005
Study 31606880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2005
Study 31606970 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous cultured fibroblasts, 3 injections administered at 4-6 week intervals.
Number of subjects: 57
Study 31606971 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene sequencing and DNA-based fragment polymorphism analysis
Number of subjects: 95
Study 31606971 — intervention group
Group type: COMPARATOR
Intervention: Conventional morphology
Number of subjects: 95
Study 31606971 — intervention group
Group type: COMPARATOR
Intervention: PCR-RFLP
Number of subjects: 95
Study 31607151 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expanding TAVR
Number of subjects: 226
Study 31607204 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting liquid methylphenidate
Number of subjects: 0
Study 31607268 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) 5 mg/kg at Weeks 0, 2, and 6, with additional doses at Weeks 14 and 22 for CAI-based responders
Number of subjects: 21
Study 31607268 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX)
Number of subjects: 21
Study 31607443 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib
Number of subjects: 48
Study 31608213 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week Interferon-based Danoprevir Regimen
Number of subjects: 0
Study 31608213 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31608217 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg-interferon Alpha-2a
Number of subjects: 0
Study 31608488 — intervention group
Group type: EXPERIMENTAL
Intervention: ACLR limb
Number of subjects: 73
Study 31608488 — intervention group
Group type: COMPARATOR
Intervention: Contralateral limb
Number of subjects: 73
Study 31609525 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 458
Study 31609525 — intervention group
Group type: COMPARATOR
Intervention: Male sex
Number of subjects: 458
Study 31609651 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 74
Study 31609771 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative diaphragm thickening fraction (TFdi,max)
Number of subjects: 115
Study 31609771 — intervention group
Group type: EXPERIMENTAL
Intervention: TFdi,max < 38.1%
Number of subjects: 115
Study 31609771 — intervention group
Group type: EXPERIMENTAL
Intervention: TFdi,max (37% [IQR, 31-45%] vs 44% [IQR, 33-58%])
Number of subjects: 115
Study 31611106 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expandable stent grafts (SESGs)
Number of subjects: 126
Study 31611106 — intervention group
Group type: COMPARATOR
Intervention: Balloon-expandable stent grafts (BESGs)
Number of subjects: 126
Study 31611259 — intervention group
Group type: EXPERIMENTAL
Intervention: MR1-independent activation of human mucosal-associated invariant T cells by Mycobacteria
Number of subjects: 0
Study 31611263 — intervention group
Group type: COMPARATOR
Intervention: Psychotic symptoms in patients with Huntington disease
Number of subjects: 1082
Study 31611617 — intervention group
Group type: EXPERIMENTAL
Intervention: Passing challenge testing
Number of subjects: 80
Study 31611617 — intervention group
Group type: COMPARATOR
Intervention: Failing challenge testing with periodic breathing
Number of subjects: 80
Study 31611759 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ketamine
Number of subjects: 24
Study 31611759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31611917 — intervention group
Group type: EXPERIMENTAL
Intervention: Compuflo® Epidural instrument
Number of subjects: 0
Study 31611917 — intervention group
Group type: COMPARATOR
Intervention: Conventional Training
Number of subjects: 0
Study 31611935 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol
Number of subjects: 131
Study 31611935 — intervention group
Group type: COMPARATOR
Intervention: 0.9% Saline
Number of subjects: 131
Study 31612072 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ESUS
Number of subjects: 101
Study 31612072 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 101
Study 31612225 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antiretroviral therapy (cART) initiated irrespective of CD4 cell count, with a median delay in initiation decreasing from 9.07 months in 2007 to 0.77 months in 2017.
Number of subjects: 61822
Study 31612225 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieving the second and third Joint United Nations Programme on HIV/AIDS 90-90-90 targets.
Number of subjects: 61822
Study 31612640 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-asparaginase in Total XVI (TXVI)
Number of subjects: 1096
Study 31612640 — intervention group
Group type: COMPARATOR
Intervention: native Escherichia coli l-asparaginase in Total XV (TXV)
Number of subjects: 1096
Study 31612640 — intervention group
Group type: EXPERIMENTAL
Intervention: asparaginase
Number of subjects: 1096
Study 31612640 — intervention group
Group type: EXPERIMENTAL
Intervention: drug effects
Number of subjects: 1096
Study 31613140 — intervention group
Group type: EXPERIMENTAL
Intervention: FreeStyle Libre
Number of subjects: 0
Study 31613140 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31613224 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic oxygenated machine perfusion (HOPE) for 2 hours via renal artery before implantation.
Number of subjects: 45
Study 31613224 — intervention group
Group type: COMPARATOR
Intervention: Conventional cold storage (control group).
Number of subjects: 45
Study 31613310 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31613328 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational norovirus vaccine
Number of subjects: 24
Study 31613706 — intervention group
Group type: EXPERIMENTAL
Intervention: Oatmeal consumption (2 servings of instant oatmeal daily for 2 weeks)
Number of subjects: 33
Study 31615411 — intervention group
Group type: EXPERIMENTAL
Intervention: dsDNA levels measured in serum
Number of subjects: 224
Study 31615411 — intervention group
Group type: EXPERIMENTAL
Intervention: PAD4 mRNA measured in circulating leukocytes
Number of subjects: 224
Study 31615411 — intervention group
Group type: EXPERIMENTAL
Intervention: MPO-DNA levels measured in serum
Number of subjects: 224
Study 31615432 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum phosphate levels
Number of subjects: 158
Study 31615432 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact parathyroid hormone (iPTH) levels
Number of subjects: 158
Study 31615432 — intervention group
Group type: EXPERIMENTAL
Intervention: C-terminal fibroblast growth factor 23 (cFGF23) levels
Number of subjects: 158